The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...
Corbus Pharmaceuticals has announced the release of an abstract for its first-in-human clinical study of CRB-701, indicating progress in its drug development pipeline. The upcoming poster ...
Corbus’ pipeline includes CRB-701 ... not imply affiliation or endorsement by these companies. Source: Corbus Pharmaceuticals Holdings, Inc. The views and opinions expressed herein are the ...
1d
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.23% to $8.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP ...
Shares of CRBP stock opened at $9.78 on Monday. The company’s fifty day simple moving average is $12.65 and its two-hundred day simple moving average is $27.00. Corbus Pharmaceuticals has a 52 ...
Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month high of $61.90. The stock has a fifty day moving average price of $12.49 and a 200-day moving average price of $26.68. Corbus ...
Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin ...
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.22% to $8.78 Tuesday, on what proved to be an all-around mixed ...
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback